Latest
By Staff Report / Thursday, October 22nd, 2015 / Latest news, Top Stories / Comments Off on 2016 Tour of California to include Thousand Oaks, Santa Barbara, Morro Bay
Thousand Oaks, Santa Barbara and Morro Bay will be part of the 2016 Tour of California professional bicycle race. Organizers announced the route at a news conference Oct. 22 in San Diego. The 2016 race will run 800 miles from San Diego to Sacramento from May 15 to May 22. This year will also be Read More →
Latest
By Staff Report / Monday, October 12th, 2015 / Health Care & Life Science, Latest news, Tri-County Public Companies / Comments Off on Amgen bone density drug shows positive results
Thousand Oaks-based pharmaceutical giant Amgen announced results Oct. 12 showing its bone density drug Prolia reduced the incidences of bone fractures in post-menopausal women with osteoporosis over 10 years. Prolia is designed to raise bone density in people with a history of osteoporosis. Amgen released the data during the annual conference of the American Society Read More →
Latest
By Marissa Nall / Friday, October 2nd, 2015 / Latest news, Nonprofits, Top Stories / Comments Off on Ventura County lags in charitable giving compared to neighboring counties
Ventura County ranks far below neighboring counties and the state in per capita nonprofit revenue, according to a 2015 state of the region report by the Ventura County Civic Alliance. In 2014, Ventura County nonprofits raised $2,153 per capita compared to $5,356 in Los Angeles County, $5,366 in the state and $6,074 in Santa Barbara Read More →
Latest
By Staff Report / Friday, September 25th, 2015 / Health Care & Life Science, Latest news, Technology, Tri-County Public Companies / Comments Off on European regulators have good news for Amgen on cancer drugs
One of the world’s most expensive cancer drugs got conditional approval from European regulators on Sept. 25. Europeans granted Thousand Oaks-based Amgen conditional approval of its rare blood cancer drug Blincyto and gave a positive evaluation of Amgen’s multiple-myeloma drug Kyprolis. Blincyto is an immunotherapy that is designed to treat a rare form of leukemia Read More →
Latest
By Staff Report / Wednesday, September 23rd, 2015 / Latest news, Technology, Top Stories / Comments Off on Study shows Amgen’s new biosimilar cancer drug safe, effective
Pharmaceuticals Amgen and Allergan announced positive Phase 3 study results of their new drug ABP 215 on Sept. 23. The drug, used to treat lung cancer, is being developed as a biosimilar to Roche Holding AG’s Avastin. ABP 215 showed clinical safety and effectiveness compared to Avastin. “Lung cancer is the leading cause of cancer Read More →
Latest
By Staff Report / Friday, September 18th, 2015 / Health Care & Life Science, Latest news, Tri-County Public Companies / Comments Off on Amgen cancer drug Kyprolis to get expedited review from FDA
An experimental multiple myeloma treatment using Amgen’s Kyprolis will get an expedited review from the U.S. Food and Drug Administration. The FDA said it will use an expedited review process to review a multiple-myeloma treatment using Kyprolis and the genric drug dexamethasone. On July 23, Amgen submitted additional data to the FDA which compared this Read More →
Latest
By Staff Report / Monday, September 14th, 2015 / Latest news, Tri-County Public Companies / Comments Off on Amgen licenses cancer drug to NatPharma
Amgen has licensed an experimental cancer drug to a Chicago biotech company founded and controlled by billionaire Patrick Soon-Shiong. NatPharma LLC is licensing the rights to AMG 337 from Thousand Oaks-based Amgen to develop and sell AMG 337. The drug is an experimental, phase-two cancer treatment. The licensing agreement is the second between Amgen and Read More →
